On episode #57 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 6/6 – 6/19/24.
Host: Daniel Griffin
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of Puscast!
Links for this episode- Viral
- Is letermovir or valganciclovir better to prevent CMV in kidney transplant recipients (JID)
- CMV antiviral therapy (GoodRx)
- Prevalence of and risk for CMV reactivation during COVID-19 pneumonia (PLoS One)
- Sofosbuvir off-label yellow fever treatment (OFID)
Bacterial - Preventing resistant gram negative bacteria through beta-lactam de-escalation in sepsis patients (CID)
- Competing risk analysis, survival analysis that aims to correctly estimate marginal probability of an event (Columbia University)
- Continuous or intermittent b-lactam infusion for critical sepsis (JAMA Network)
- Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock (JAMA Network)
- Phoenix sepsis score and risk in children with cancer (JAMA Network)
- New recognized spotted fever group Rickettsia in Northern California (Emerging Infectious Diseases)
- Screening for mycobacterium tuberculosis (Transplant Infectious Disease)
Fungal - Potential sexual transmission of Tinea pubogenitalis from TMWII (JAMA Dermatology)
- Household transmission of tinea infection (OFID)
- Drug-resistant oral candidiasis in HIV infected patients (BMC Infectious Disease)
Parasitic - Handheld digital microscope for rapid and comprehensive screening for urogenital and gastrointestinal schistosomiasis (American Journal of Tropical Medicine and Hygiene)
- Scorecard approach to eliminate onchocerciasis (Am J Trop Med Hyg)
Miscellaneous - Association between antibiotic receipt and provider rating (OFID)
- Infectious diseases and infection control prevention strategies when on ECMO (Perfusion)
Music is by Ronald Jenkees
Fler avsnitt av Infectious Disease Puscast
Visa alla avsnitt av Infectious Disease PuscastInfectious Disease Puscast med Vincent Racaniello finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
